Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 Study of Baloxavir Marboxil 2% Granules in Pediatric Influenza Patients (<20 kg)
jRCT2080224512Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of baloxavir marboxil in influenza, sponsored by Shionogi & Co., Ltd. Primary endpoints: Safety and tolerability of single-dose baloxavir marboxil 2% granules and Pharmacokinetics of baloxavir marboxil 2% granules. Started Jan 2019; status: completed.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2080224512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224512.